Clin2
NCT00004847Likely a fitRecruiting

Understanding and Diagnosing Pheochromocytoma and Paraganglioma

PheochromocytomaEndocrine DiseaseEndocrine Diseases

Treatments studied

Part of Cancer, Hormones & metabolism clinical trials.

This study helps doctors better understand and diagnose pheochromocytoma and paraganglioma—rare tumors that release stress hormones and cause high blood pressure and other symptoms. Researchers will study your medical history, blood and urine tests, imaging scans, and genetic information to improve how these conditions are found and understood.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
3,000 people
Ages
3 years to 120 years
Study type
Interventional

Who can take part

  • You are at least 3 years old with suspected or confirmed pheochromocytoma/paraganglioma (a rare hormone-releasing tumor)
  • You have high levels of stress hormones in blood or urine, imaging findings suggestive of the tumor, or a personal or family history of this condition
  • You have a regular doctor or endocrinologist (hormone specialist) who can help manage your care
  • If you are a woman who could become pregnant, you cannot be pregnant or breastfeeding during the study
  • You do not have severe heart problems or require kidney dialysis
  • For imaging scans, you must be able to lie still and be willing to return to NIH for follow-up visits

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05636540Recruiting· Early Phase 1
PET/CT scan test for a tumor protein in these rare tumors

This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.

Philadelphia, Pennsylvania
NCT03206060Recruiting· Phase 2
Lu-177 DOTATATE for hard-to-remove pheochromocytoma or paraganglioma

This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.

Bethesda, Maryland
NCT03344016Recruiting
Study of pheochromocytoma and paraganglioma in patients

This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.

Zurich
NCT06444607Recruiting
Immune study of hereditary pheochromocytoma tumors

This study looks at how the immune system responds to rare adrenal or nerve-related tumors (pheochromocytoma and paraganglioma). Researchers want to understand the tumor's environment, which may help improve future treatments.

Nijmegen, Gelderland
NCT03160274Recruiting
Genetic testing for certain adrenal and nerve tumors

This study looks at genetic (DNA) changes in people with pheochromocytoma or paraganglioma and related conditions. It may help clarify why these conditions happen and how they run in families.

San Antonio, Texas
NCT06813742Recruiting
New PET scan for pheochromocytoma

This study uses a special PET scan (called 18F-mFBG) to get clearer pictures of pheochromocytoma, a rare adrenal tumor. It may help doctors better understand your tumor and guide treatment.

Hangzhou, Zhejiang

Hear when a new Pheochromocytoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.